Molecure, the biotechnology innovator striving to develop breakthrough medicines to tackle some of the world’s most challenging diseases, is proud to announce that it has closed a successful SPO and entered into subscription agreements for all 2,776,000 H shares offered by way of private placement, raising a gross value of approximately PLN 50 million.
This marks a major step forward in the company’s journey, and will enable Molecure to apply their globally unique expertise in medicinal chemistry and biology to explore and develop first-in-class small-molecule drugs that directly modulate protein activity and mRNA function in pursuit of a range of curative treatments.
Molecure S.A. is delighted to report the successful completion of the H-share offering, which was met with enthusiastic investor interest, both from existing and new investors. We are immensely grateful to everyone who participated in the offering, demonstrating their trust in Molecure’s vision and growth potential.
Despite the prevailing market conditions, the oversubscribed offering was an impressive accomplishment. The proceeds of the offering will be employed to fund Molecure’s ambitious efforts to develop treatments for otherwise uncurable diseases.
The offering of funds will help finance the Strategic Plans set in place from 2023-2025, which has a primary focus on two of the Company’s top Innovational Programs, OATD-01 and OATD-02. OATD-01 is a revolutionary first-in-class chitotriosidase 1 (CHIT1) inhibitor designed to treat interstitial lung disease, whereas OATD-02 is a revolutionary dual arginase inhibitor developed for cancer treatment.
Innovative new technologies are being leveraged to revolutionize early-stage treatments and therapies. Our portfolio of programmes includes breakthrough small-molecule drug technology that can influence mRNA translation and therapeutic strategies targeting little-explored proteins.
To further push research boundaries, advanced machine learning and generative artificial intelligence (GenAI) practices are being implemented. It’s an exciting time for us as we work towards creating powerful new treatments that can make a difference in people’s lives.
Molecure estimates that investing in their strategy from mid-2023 to the end of 2025 will require an estimated capital expenditure of PLN 250 million. With this investment, they hope to achieve greater operational efficiency, grow their business, and further develop their technological capabilities.
Molecure is blazing a trail on the Polish biotech scene – they have two proprietary compounds that are in the first phase of clinical trials. With the aim of securing a high-value partnership agreement over the next few years, which could deliver tangible rewards to Shareholders, Molecure is working hard to build the value of these programmes. They are set to make waves in the years to come.
Our strategy focuses on transforming our intellectual property into commercial success, with a goal of securing a partnership agreement for at least one of our clinical assets before 2025 and building collaborations for our programs at earlier development stages.
The funds from our share offering, combined with other funding sources, give us the resources and strength to make progress with our programs and have more power in partnering negotiations. We are so encouraged that investors saw the value in our achievements and strategy, helping us to move closer to our innovation goals.